Can (and will) governments afford personalized medicine?

Personalized Medicine

Volumn 7, Issue 5, 2010, Pages 587-595

  Taylor, David ^a   Al Saeed, Eman ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

costeffectiveness; intellectual property; investment; licensing; marketing; personalized medicine; research funding; trials

Indexed keywords

AZATHIOPRINE; GEFITINIB; IMATINIB; TRASTUZUMAB; WARFARIN;

BREAST CANCER; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG INDUSTRY; ELDERLY CARE; FUNDING; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LUNG CANCER; MARKETING; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 77957585608     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.51     Document Type: Review

References (31)

1. The International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
2. Tang J, Kaslow RA: Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics 4(3), 171-174 (2004). (Pubitemid 38786555)
3. Serrano D, Lazzeroni M, Zambon CF et al.: Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULTlAl genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics doi:10.1038/tpj.2010.17 (Epub ahead of print) (2010).
4. Lesko LJ: The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84(3), 301-303 (2008).
5. Mega JL, Close SL, Wiviott SD et al.: Cytochrome P450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
6. Jain KK: Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 5(3), 331-336 (2004).
7. Ginsburg GS, Willard HF: Genomic and personalized medicine: foundations and applications. Transl. Res. 154(6), 277-287 (2009).
8. Bradfield R, El-Sayed H: Four scenarios for the future of the pharmaceutical industry. Tech. Strat. Manag. 21(2), 195-212 (2009).
9. McGuire AL, Burke W: An unwelcome side effect of direct-to-consumer personal genome testing. JAMA 300(22), 2669-2671 (2008).
10. Shastry BS: Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics 6(1), 16-21 (2005).
11. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E: The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics 6(1), 3-7 (2005). (Pubitemid 43118304)
12. Ma BBY, Loong H: Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Per. Med. 7(2), 121-124 (2010). •• Robust overview of personalized cancer therapy development.
13. Aspinall MG, Hamermesh RG: Realizing the Promise of Personalized Medicine. Harvard Business Publishing, NY, USA (2007). • Review stressing the need to modernize business models, regulatory systems and reimbursement strategies in order to permit/promote personalized medicines development.
14. Global Health Equity Group: Strategic Review of Health Inequalities in England post 2010 (The Marmot Review). UCL Department of Epidemiology & Public Health, London, UK (2010). • Magisterial analysis of the underlying social causes of health inequalities.
15. Taylor D, Bury M: Chronic illness, expert patients and care transition. Sociol. Health Illn. 29(1), 27-45 (2007). • Describes the theoretical basis of the care transition concept.
16. Hall SS: Personalized medicine's bitter pill. Technol. Rev. 106(1), 62-70 (2003).
17. Garber AM, Tunis SR: Does comparativeeffectiveness research threaten personalized medicine? N. Engl. J. Med. 360(19), 1925-1927 (2009).
18. McGuire A, Raikou M: Inferring the Value of Medical Research to the UK. Working Paper 5/2007. LSE Health, London, UK (2007). • Important attempt to quantify the overall social/economic returns derived from life expectancy gains in the period 1970-2000.
19. La Vecchia C, Bosetti C, Lucchini F et al.: Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann. Oncol. 21(6), 1323-1360 (2009).
20. Frueh FW: Considerations for a business model for the effective integration of novel biomarkers into drug development. Per. Med. 5(6), 641-649 (2008).
21. Walko CM, McLeod H: Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat. Clin. Prac. Oncol. 6(3), 153-162 (2009).
22. Marin D, Bazeos A, Mahon FX et al.: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28(14), 2381-2388 (2010).
23. Royal Society: Personalized Medicines: Hopes and Realities. The Royal Society, London, UK (2005). Substantive analysis of the potential for personalized medicines development, and the likely barriers to it and benefits of its achievement.
24. Kanavos P, Sullivan R, Lewison G et al.: The Role of Funding and Policies on Innovation in Cancer Drug Development. The European Institute of Oncology, Brussels, Belgium (2009).
25. Melzer D, Raven A, Ling T, Detmer D, Zimmern R: Pharmacogenetics: policy needs for personal prescribing. J. Health Serv. Res. Policy 10(1), 40-44 (2005).
26. European Commission DG Research: Proceedings of: Clinical Trials and Regulatory Aspects. (2010) (In press).
27. Eichler HG, Pignatti F, Flamion B, Jeufkens H, Breckenridge A: Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature 7, 818-826 (2008). •• Important article on the need to re-engineer regulatory approaches to facilitating early patient access to new drugs.
28. Niese D: Clinical trials for personalized medicines: developing medicines and companion diagnostics. Presented at: European Commission (DGResearch) Workshop on Personalized Medicines. Brussels, Belgium, 3-4 June (2010).
29. Reichert JM, Wenger JB: Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13 (1-2), 30-37 (2008).
30. Wilking N, Jonsson B, Hogberg D: Comparator Report on Patient Access to Cancer Drugs in Europe. The Karolinska Institute, Stockholm, Sweden (2009).
31. Organization for Economic Cooperation and Development (OECD): Pharmaceutical Pricing in a Global Market. OECD, Paris, France (2008).